NG25 是TAK1(IC50:149 nM)和MAP4K2(IC50:21.7 nM)的双抑制剂。

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.

NG25 sensitizes the breast cancer cells to Dox treatment in vitro. This combination may be an effective and feasible therapeutic option maximizing Dox efficacy and meanwhile minimizing Dox side effects in treating breast cancer[1].

Breast cancer cells were seeded in 12-well plates at 2?×?10^3 cells per well, then incubated with Dox alone or Dox with NG25 at indicated concentrations after 72?h and then were cultured in fresh medium without drug.?Two weeks later, cells were fixed and stained with methanol/crystal violet for 10?min, and photographed.?Each experiment was performed in triplicates[1].

1315355-93-1

C29H30F3N5O2

537.587

DMSO:100 mg/mL (186.02 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years